First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Study identifier:D4194R00005

ClinicalTrials.gov identifier:NCT03798535

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Medical condition

NSCLC

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1156

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 19 Dec 2018
Estimated Primary Completion Date: 07 Jun 2024
Estimated Study Completion Date: 07 Jun 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Apr 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria